Special Issue "Allergic Reactions to Current Available COVID-19 Vaccines"
Deadline for manuscript submissions: 31 March 2023 | Viewed by 23208
Interests: asthma; severe asthma; rhinosinusitis with and without nasal polyps; AIT; type 2 diseases; asthma comorbidities; digital medicine; artificial intelligence applied to immunocenters; mAB therapies for severe asthma (biologicals); COVID-19; precision medicine; personalized medicine
2. IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
Interests: allergy; anaphylaxis; drug allergy; asthma; severe asthma; rhinosinusitis with and without nasal polyps; biologicals; precision medicine
Adverse hypersensitivity reactions to SARS-CoV-2 vaccines for the prevention of Coronavirus disease 2019 (COVID-19) have been reported since the initiation of the global vaccination campaign. These cases have elicited a lot of clamor, prompting the necessity to determine the real prevalence of allergic reactions to the vaccines, especially because no cases of anaphylaxis were reported in randomized clinical trials with the vaccine. A large number of studies have been published in the latest months about this topic, confirming that hypersensitivity reactions to COVID-19 vaccines and their prevention are one of the hot topics in the allergy and clinical immunology field.
The underlying immunological mechanisms of hypersensitivity reactions to the COVID-19 vaccines are only partially understood and urgently need clarification.
Precisely for these reasons, this Special Issue will focus on the re-assessment of published evidence and the re-evaluation of procedures and protocols for the prevention and management of this specific aspect, also taking into consideration patients’ psychological aspects and new tools such as digital health technologies.
Dr. Francesca Puggioni
Dr. Enrico Marco Heffler
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.